Medpace Holdings Inc Cash Flow Conversion Efficiency
Medpace Holdings Inc cash flow conversion efficiency. Based on the latest financial reports, Medpace Holdings Inc (MEDP) has a cash flow conversion efficiency ratio of 0.373x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($162.01 Million) by net assets ($433.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Medpace Holdings Inc (2014–2025)
Cash flow conversion efficiency of Medpace Holdings Inc from 2014 to 2025. This chart illustrates how Medpace Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Medpace Holdings Inc for real-time trading data and today's change.
Medpace Holdings Inc Cash Flow Conversion Ratio Explained
Medpace Holdings Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Medpace Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medpace Holdings Inc ranked by their cash flow conversion efficiency. Also see MEDP market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Leidos Holdings Inc
NYSE:LDOS
|
0.059x |
|
Zhen Ding Technology Holding Ltd
TW:4958
|
0.073x |
|
Hengli Petrochemical Co Ltd
SHG:600346
|
0.009x |
|
Evolution AB (publ)
ST:EVO
|
0.068x |
|
Toast Inc
NYSE:TOST
|
0.070x |
|
Jiangsu Hengli Hydraulic Co Ltd
SHG:601100
|
0.020x |
|
Beiersdorf Aktiengesellschaft
F:BEIA
|
0.019x |
|
ING Bank Śląski SA
WAR:ING
|
0.906x |
Annual Cash Flow Conversion Efficiency for Medpace Holdings Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Medpace Holdings Inc from 2014 to 2025. Review MEDP free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $459.07 Million | $713.22 Million | 1.554x | +110.67% |
| 2024-12-31 | $825.54 Million | $608.82 Million | 0.737x | -4.88% |
| 2023-12-31 | $558.95 Million | $433.37 Million | 0.775x | -22.80% |
| 2022-12-31 | $386.39 Million | $388.05 Million | 1.004x | +263.44% |
| 2021-12-31 | $952.93 Million | $263.33 Million | 0.276x | -13.92% |
| 2020-12-31 | $805.78 Million | $258.68 Million | 0.321x | +15.50% |
| 2019-12-31 | $726.28 Million | $201.87 Million | 0.278x | +4.68% |
| 2018-12-31 | $589.70 Million | $156.58 Million | 0.266x | +37.29% |
| 2017-12-31 | $503.53 Million | $97.39 Million | 0.193x | +28.76% |
| 2016-12-31 | $610.71 Million | $91.73 Million | 0.150x | -27.67% |
| 2015-12-31 | $413.47 Million | $85.87 Million | 0.208x | +11.01% |
| 2014-12-31 | $401.97 Million | $75.20 Million | 0.187x | -- |
About Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medica… Read more